Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasis

Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results From STRIDE and OLE,” a poster by April W. Armstrong, MD, MPH, et al presented as part of the “Best of the Best at Maui Derm” late breakers session at Maui Derm Hawaii 2026.

At Week 12 of the STRIDE Phase 2 trial, patients receiving envudeucitinib 40 mg twice daily achieved significantly higher rates of absolute PASI ≤1, ≤2, and ≤3, as well as BSA ≤1% and DLQI 0/1, compared with placebo. These responses were sustained and further improved through 52 weeks in the open-label extension.

“Progressive improvements in skin clearance and quality of life were observed over time,” the authors reported, reinforcing the clinical relevance of treat-to-target outcomes.

The safety profile remained consistent through one year, with upper respiratory tract infections, headache, and nasopharyngitis among the most commonly reported adverse events.

“This poster is really about raising the bar,” said Linda Stein Gold, MD. “The National Psoriasis Foundation targets are telling us we need to aim for body surface area of 1% or less when possible, and this oral TYK2 inhibitor is getting a meaningful proportion of patients to that level of control.”

Dr. Stein Gold added, “When you see about 60% of patients reaching that very high threshold by 52 weeks, along with improvements in quality of life, that tells us this could be a very viable long-term oral option.”